Octavio Alejandro Fuentes Méndez

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj… Review synthesises international guidance on lutetium-177 PSMA radioligand therapy (177Lu-PSMA-RLT) in #ProstateCancer , focusing on metastatic castration-resistant disease. Major societies, including EAU, NCCN, ASCO, AUA/SUO, and CUA, endorse 177Lu-PSMA-617 after prior ARPI and taxane therapy, supported by VISION and TheraP trial data. Emerging evidence from PSMAfore is expanding use into earlier treatment settings. Current recommendations emphasise PSMA-positive patient selection, standardised dosing, androgen deprivation therapy continuation, and multidisciplinary management. @declangmurphy @DrMHofman @AzadOncology @RenuEapen @lawrentschuk @drMPerera @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Starting today!!! #IPCS2026 & #APCCC2026 Check the wonderful agenda ✅ onlineevent.ch/APCCC/2026 in person and online📤 Great faculty @Silke_Gillessen @Ecastromarcos @DrYukselUrun @tompowles1 @EAntonarakis @oncodaily @OncoAlert @urotoday

El maestro fue alumno. El hábil fue torpe. El experto fue alguna vez ignorante. El campeón fue novato. Somos procesos.

New in @UrolOncol Our review on “Etiology of Testosterone Deficiency After RP” highlights an underrecognized consequence of RP: • ~1 in 3 men develop testosterone deficiency • Likely due to venous disruption & ischemia • Most recover within 12 months ➡️ Takeaway: Not all post-RP low libido, or delayed recovery is “expected”—testosterone matters @faysal_a_yafi @Mo_Moukhtar #prostatecancer #MensHealth sciencedirect.com/science/articl…

6/ Watch the @gu_onc #PRIMARY2 episode now! youtu.be/jvWis1RcXz0

3/ Importantly, #PRIMARY2 also reduced the diagnosis of insignificant prostate cancer - helping move us toward a smarter diagnostic pathway with fewer unnecessary biopsies, less overdiagnosis, and more precise targeting for those who do need biopsy.

2/ The key finding: adding PSMA PET/CT to current standard-of-care halved the number of prostate biopsies. Biopsy was avoided in 49% of men, without missing clinically significant prostate cancer.

Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. uroweb.org/news/scan-that…

Extended vs limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk #ProstateCancer: 10 years of follow up - oncological outcomes from a randomized phase 3 trial. Presented by Matheus Ruggeri. #EAU26 written coverage by @zklaassen_md > bit.ly/40vh9q4 @Uroweb

#EAU26 Intensification strategies in HR-NMIBC Dr. Xylinas reviews CREST, ALBAN, POTOMAC 🔹 ALBAN ❌ atezolizumab + BCG → no EFS benefit 🔹 CREST ✅ sasanlimab + BCG → improved EFS (HR 0.68) 🔹 POTOMAC ✅ durvalumab + BCG → improved DFS (HR 0.68) 🎯 Benefit mainly driven by ↓ high-grade recurrence 🚩BCG maintenance for 2y remains critical @uroweb @urotoday

📣@ChapinMD presents best systemic therapy trial +/- prostatectomy n=120 randomised phase II trial in #prostatecancer. No observed benefit for prostatectomy 🔪🩸. Ongoing recruitment for SWOG-1802, pls support this important clinical trial 👏🏽#pcsm #EAU26

[68Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX) link.springer.com/article/10.100… This prospective trial compared [68Ga]PSMA-11 PET/CT and mpMRI in men with suspected #ProstateCancer after a prior negative biopsy. Among 130 patients, PET/CT demonstrated higher diagnostic accuracy for clinically significant disease than mpMRI. PSA density, PRIMARY score, SUVratio, and PI-RADS predicted significant cancer. Investigators developed the PRIMER nomogram, which showed strong performance (AUC 0.896) for predicting clinically significant prostate cancer before repeat biopsy. Egesta Lopci, @FasuloVittorio @RobPeschechera @GLughezzani @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists

PEACE-2 Presented at #GU26 asco.org/abstracts-pres… PEACE-2 evaluated whether adding upfront cabazitaxel to long-term ADT and prostate radiotherapy improves outcomes in very high-risk localized #ProstateCancer . In this 2×2 factorial phase III trial of 761 patients, no interaction was seen with pelvic radiotherapy☢️, and cabazitaxel did NOT🚫improve clinical progression-free survival (HR 1.11), with similar overall survival across arms after a median 85 months. Toxicity was higher with cabazitaxel, and prostate cancer–related deaths were rare. Karim Fizazi @PaulSargos Igor Latorzeff @AFUrologie @EnriqueGallar12 @PBlanchardMD @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists

Phase 3 LITESPARK-022 trial Presented at #GU26 dailynews.ascopubs.org/do/litespark-0… The addition of belzutifan to one year of pembrolizumab after nephrectomy in patients with high-risk clear cell RCC significantly improved disease-free survival compared with pembrolizumab alone, lowering📉the risk of recurrence or death by 28% (HR 0.72). At 24 months, DFS rates were 80.7% with the combination versus 73.7% with pembrolizumab🧪 Although grade ≥3 adverse events were more frequent—including anemia, hypoxia, and elevated liver enzymes—they were generally manageable with dose adjustments and supportive care. Source Linked: ASCO Daily News @DrChoueiri @motzermd @DrIacovelli @DrYukselUrun @elena_verzoni @tompowles1 @OncoAlert 🚨

Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer. sciencedirect.com/science/articl…

Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer pfizer.com/news/press-rel…

Reunión de Egresados del Departamento de Urología del @incmnszmx durante el reciente Congreso 2025 de la @smumexico Una gran oportunidad para convivir con excelentes amigos y grandes especialistas.

#SMU #CongresoNacionalUrologia2025

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms). 🔹 PC-specific survival 98% 🔹 Slight ↓ in biochemical failure with WPRT 🔹 More grade 2 GI adverse events ⁉️how to reconcile with POP-RT trial in PSMA era? Lower risk cohort? #ASTRO25 #RadOnc

Recaída bioquímica #cancerprostata @RodRogSan presentando en @SMEOMX 🔆🤩👨🏻‍⚕️🦀🌍 🔴RT de salvamento infrautilizada 🟢Q vamos irradiar: lecho, gl! 🟠Tiempo de tx hormonal: 6 vs 24 m 🔵 EMBARK study: ADT vs Enza vs Enza + ADT